The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be improved through formulation and delivery approaches. Here, we attached small molecule TLR-7/8a to polymer scaffolds (polymer-TLR-7/8a) and evaluated how different physicochemical properties of the TLR-7/8a and polymer carrier influenced the location, magnitude and duration of innate immune activation in vivo. Particle formation by polymer-TLR-7/8a was the most important factor for restricting adjuvant distribution and prolonging activity in draining lymph nodes. The improved pharmacokinetic profile by particulate polymer-TLR-7/8a was also associated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cell immunity. We extended these findings to the development of a modular approach in which protein antigens are site-specifically linked to temperature-responsive polymer-TLR-7/8a adjuvants that self-assemble into immunogenic particles at physiologic temperatures in vivo. Our findings provide a chemical and structural basis for optimizing adjuvant design to elicit broad-based antibody and T cell responses with protein antigens.
Although vaccines that mediate protection through antibodies are in routine clinical use 1 , vaccines that generate robust and durable T cell immunity are still needed for protection against certain infections (such as malaria 2 and tuberculosis 3 ) and as therapies for cancer 4 . One means of improving T cell immunity to vaccines is through the rational choice of adjuvants formulated with defined protein or peptide antigens 5 . Some of the most effective adjuvants for promoting T cell immunity are Toll-like receptor agonists (TLRa), which stimulate distinct populations of antigen-presenting cells (APCs), particularly dendritic cells (DCs), to present antigen, express co-stimulatory molecules and produce selective cytokines that drive T cell responses 6 .
The formulation and delivery of TLRa play a critical role in influencing their in vivo activity when used with protein-based vaccines [7] [8] [9] . Accordingly, linking TLRa directly to protein antigen [10] [11] [12] and coadministering protein with particle-based carriers 9,13-17 of TLRa have each been shown to markedly improve both T cell and antibody responses. Recent reports show that the ability of formulations to spatially restrict TLRa activity to the sites of vaccine administration and draining lymph nodes are critical for enhancing antibody and T cell-mediated protection 18, 19 . The capacity of particulate delivery platforms to target distinct APC populations in lymph nodes on the basis of size has been studied [20] [21] [22] [23] , but it is not clear how these and other physical and chemical properties of TLRa delivery influence the location, magnitude and duration of innate immune activation to enhance T cell immunity to protein vaccines in vivo.
Here, we investigated how delivery of TLRa on biocompatible polymer scaffolds can modulate innate immune activation in vivo to enhance T cell immunity to protein antigens. Small molecule agonists of endosomally localized TLR-7 and TLR-8 (TLR-7/8a) were selected as model TLRa for these studies because they have been shown in both humans 24 and mice 6, 25 to activate all major DC subsets and macrophages and induce the production of specific cytokines (IL-12 and type I interferons (IFNs)) that promote T cell immunity 26 . In terms of other TLRa to consider as adjuvants, while the TLR-9a CpG has been used as a model adjuvant for vaccine formulations in a number of preclinical mouse studies 16, 18 , the more restricted expression of TLR-9 to pDCs and B cells in humans 6 may limit its effectiveness for inducing T cell immunity when used in protein subunit vaccines in patients. In contrast, formulations with combined TLR-7/8a may be potentially more clinically translatable for enhancing T cell immunity due to the In vivo characterization of the physicochemical properties of polymer-linked tlr agonists that enhance vaccine immunogenicity A r t i c l e s broader expression of TLR-7 and TLR-8 across all major human APC subsets 26 . Although the US Food and Drug Administration's approval of two imidazoquinoline-based TLR-7/8a (imiquimod and resiquimod (R848)) for treating skin pathologies 27, 28 provides evidence to support their safety and efficacy as immunotherapies in humans, the unfavorable pharmacokinetic properties of these agonists for use in vaccines reduces their effectiveness for inducing adaptive immunity and gives rise to systemic toxicity 29, 30 , thereby presently limiting TLR-7/8a to topical uses.
To improve their pharmacokinetics and evaluate the ways that various properties of delivery influence their activity for use in vaccines, we linked TLR-7/8a to polymers (creating molecules referred to as Poly-7/8a) in a combinatorial process and evaluated how different physicochemical properties, such as the density of TLRa arrayed on polymers and inducible particle formation, influenced innate immune activation, adjuvant distribution, kinetics and uptake by different APCs in vivo. The data show that particle formation by Poly-7/8a is critical for enhancing the magnitude and duration of innate immune activation in draining lymph nodes while reducing systemic distribution and toxicity. The improved activity of particleforming Poly-7/8a was associated with T H 1 CD4 + and CD8 + T cell mediated-protection in two infectious challenge models and enhanced T H 1-skewed antibody responses. To extend these findings and develop an approach that combines the benefits of soluble antigens and adjuvants-high chemical definition and stability-with the superior activity of particulate vaccines, we developed temperatureresponsive polymers co-delivering TLR-7/8a and protein antigen that exist as water-soluble molecules in vitro at room temperature but undergo temperature-dependent particle formation in vivo. This report highlights the flexibility and chemical tunability of using polymers to modulate delivery of antigen and TLRa so as to enhance innate and adaptive immunity in vivo.
RESULTS
In vivo screening of polymer-TLR-7/8a conjugates The first studies focused on optimizing the delivery of small molecule TLR-7/8a ( Supplementary Fig. 1a ) on polymer carriers. We chose HPMA-based polymers ( Supplementary Fig. 1b ) as scaffolds on the basis of their demonstrated safety in humans and because they provide a modular platform for delivering bioactive molecules 31, 32 . To evaluate how properties such as the density of TLR-7/8a arrayed on the polymer or the chemical composition (hydrophobic versus hydrophilic, longer or shorter) of the linkers anchoring the agonist to the polymer backbone ( Supplementary Fig. 1a ) influence biological activity, we generated a library of different Poly-7/8a ( Fig. 1a,b and Supplementary Fig. 1b ) through combinatorial synthesis ( Supplementary Fig. 2 ) and then screened them in vivo. As the hydrocarbon backbone of HPMA polymers is nonbiodegradable, Poly-7/8a conjugates were kept at or below the previously reported glomerular filtration limit (~45 kDa 33 ) to facilitate renal excretion.
Increasing the density of TLR-7/8a arrayed on polymers resulted in substantially higher lymph node production of cytokines critical for priming T H 1 CD4 + and CD8 + T cell immunity (IL-12, IP-10 and IFNs), even though the same total dose of TLR-7/8a (12.5 nmol) was administered ( Fig. 1c,d and Supplementary Figs. 3 and 4a-d) .
Notably, the enhanced in vivo activity observed for increasing densities of TLR-7/8a was associated with Poly-7/8a assembling into particles in aqueous conditions ( Fig. 1d,e ). Whereas Poly-7/8a with low to intermediate agonist densities (1-4 mol% TLR-7/8a) exist predominantly as unimolecular polymer coils (PC, ~10-to 20-nm diameter) and induce no measurable cytokine production in vivo, Poly-7/8a with high agonist density (8-10 mol% TLR-7/8a) assemble into submicron polymer particles (PP, ~700-nm diameter) and induce substantially higher lymph node cytokine production than the unformulated small molecule TLR-7/8a (SM 7/8a) and Poly-7/8a with low agonist density (1-2 mol% 7/8a) that exist as unimolecular polymer coils ( Fig. 1d-f and Supplementary Fig. 4a-d) . These data show that particle formation, increasing densities of TLR-7/8a on the polymers, or both are critical for in vivo cytokine responses by Poly-7/8a. Such innate cytokine production by particle-forming Poly-7/8a is dependent on TLR-7 and independent of caspase 1/11 signaling, a major inflammasome pathway that is activated by certain particulate delivery systems 34 (Supplementary Fig. 4e,f) .
Particulate Poly-7/8a promotes local retention and APC uptake Cytokine production by lymph node APCs depends on the capacity of TLR-7/8a to access endosomally localized receptors within those cells 35 . However, the relative efficiency of TLR-7/8a delivery for targeting cells by different carrier morphologies is presently unknown. Thus, we assessed how the morphology of the TLR-7/8a carrier, either small molecule (SM 7/8a), polymer coil (PC-7/8a) or particleforming polymer (PP-7/8a), influences uptake by immune cells in lymph nodes draining the site of immunization following their subcutaneous administration in the hind footpads of mice. All TLR-7/8a constructs were fluorescently labeled ( Supplementary Fig. 5a ) to facilitate in vivo tracking. PC-7/8a and PP-7/8a were prepared with the same density of TLR-7/8a, while an inert hydrophobic ligand was attached to PP-7/8a to induce particle formation ( Supplementary  Figs. 4a,b and 5a) . Whereas the unformulated SM 7/8a exhibited systemic distribution ( Fig. 2a ) and rapid clearance ( Fig. 2b) , both PC-7/8a and PP-7/8a were primarily focused at the injection site ( Fig. 2a ) and persisted in draining lymph nodes for up to 20 d ( Fig. 2b) . Moreover, PP-7/8a led to ~400-and 4-fold higher levels of TLR-7/8a (area under the concentration-time curve, AUC) in draining lymph nodes as compared with SM 7/8a and PC-7/8a, respectively ( Fig. 2b) . Analysis of lymph node sections by confocal microscopy (Fig. 2c ) provided additional spatiotemporal resolution by revealing that PP-7/8a localized primarily within APCs situated in or near the medullary and cortical lymphatic sinuses of draining lymph nodes on day 1, but was also associated with a large influx of migratory APCs in the T cell zone at later time points (days 4 and 8). In contrast, only a limited amount of PC-7/8a was detectable and localized with APCs in the lymph node periphery. The SM 7/8a was undetectable in all lymph node sections ( Fig. 2c) , confirming that the low-molecular-weight agonist was rapidly eliminated (Fig. 2b) .
Further assessment of specific lymph node APC populations by flow cytometry (Supplementary Fig. 5b,c) showed that PP-7/8a leads to a substantially greater (>10-fold) influx of CD11c + DCs and macrophages/monocytes (CD11c − CD11b hi F4/80 + ) as compared with SM 7/8a and PC-7/8a ( Fig. 2d) . Furthermore, although PC-7/8a and PP-7/8a localized in draining lymph nodes with similar proportions of total DCs (~40-60%) and macrophages/monocytes (~60-80%) ( Fig. 2e) , the relative amount of material taken up by APCs on a percell basis was markedly higher (~10-to 20-fold) for PP-7/8 as compared with PC-7/8a ( Fig. 2f) . Further stratification of DC subsets revealed uptake of PP-7/8a by monocyte-derived DCs (CD11c + CD11b hi F4/ 80 lo CD8 − B220 − ) as well as the mixed population of migratory and lymph node-resident CD8 − DCs (CD11c + CD11b lo CD8 − B220 − ) and lymph node-resident CD8 + DC (CD11c + CD11b − CD8 + B220 − ) populations at day 1, whereas the CD11c + CD8 − B220 − population enriched for migratory APCs accounted for the majority of uptake at later time points ( Supplementary Fig. 5d ). These findings are consistent with npg A r t i c l e s Figure 1 Increasing densities of TLR-7/8a arrayed on polymer carriers is associated with particle formation and enhanced lymph node cytokine production. (a) Poly-7/8a were generated by reacting linear biocompatible polymers with nucleophilic TLR-7/8a. (b) Combinatorial synthesis was used to generate Poly-7/8a with varying linker-group composition and TLR-7/8a density. The density of agonist arrayed on the polymers (mol% 7/8a) is reported as the percentage of monomers that are linked to TLR-7/8a (for example, 10 mol% 7/8a indicates 10 out of 100 monomers are linked to TLR-7/8a). (c) Different Poly-7/8a (12.5 nmol) or controls (HPMA polymer alone or small molecule TLR-7/8a (SM 7/8a)) were subcutaneously administered into hind footpads of mice. After 24 h, lymph nodes draining the site of immunization were harvested and processed to generate a cell suspension that was cultured for 8 h and then evaluated for the presence of IL-12p40 (n = 4 per group). (d) Polymer controls (see Supplementary Fig. 4a ,b), SM 7/8a or Poly-7/8a with increasing densities of TLR-7/8a (normalized to 12.5 nmol TLR-7/8a) were evaluated for particle formation by dynamic light scattering (n = 3) and the capacity to induce IP-10 (n = 6 per group) and IL-12p40 (n = 6 per group) cytokine production in draining lymph nodes at 24 h and 96 h, respectively, after administration. (e) Size-distribution plots from dynamic light scattering are shown for selected samples; a confocal microscopy image is shown for a Poly-7/8a with 10 mol% 7/8a that forms particles in aqueous conditions. (f) Data from d for which Poly-7/8a with 1-2 mol% 7/8a that exist as unimolecular polymer coils (PC-7/8a) or Poly-7/8a with 8-10 mol% 7/8a that exist as submicron polymer particles (PP-7/8a) are grouped together to correlate the effect of Poly-7/8a morphology with lymph node IP-10 (n = 12 per group) and IL-12p40 (n = 12 per group). In vivo screens are representative of two independent experiments. Data on linear axes are reported as mean ± s.e.m. Data on log scale are reported as geometric mean with 95% confidence interval (CI). Comparison of multiple groups for statistical significance was determined using Kruskal-Wallis ANOVA with Dunn's post hoc test; Student's t-test was used for comparison of two groups; ns, not significant (P > 0.05); **P < 0.01. SM, small molecule; PC, polymer coil; PP, polymer particle.
npg
A r t i c l e s earlier reports that sub-micron-sized particles (>100 nm), such as PP-7/8a, are primarily trafficked to lymph nodes by migratory APCs 21 .
TLR-7/8a density potentiates innate and adaptive immunity
We next assessed how carrier morphology and properties of the linked TLR-7/8a influenced the magnitude and spatiotemporal characteristics of innate immune activation in vivo. The locally restricted PP-7/8a was associated with significantly increased expression of co-stimulatory molecules by DCs and macrophages/monocytes ( Fig. 3a,b and Supplementary Fig. 6a,b ) and with enhanced cytokine production ( Fig. 3c) , in draining lymph nodes. Analysis of APC populations in the spleen showed that only the systemically distributed SM 7/8a (see Fig. 2a ) induced splenic DC activation (Supplementary Fig. 6c ) and serum cytokines ( Supplementary  Fig. 6d ). Notably, PC-7/8a was largely inactive in vivo, despite efficient local retention. We hypothesized that increasing the molecular weight of PC-7/8a might lead to improved activity in vivo; however, PC-7/8a across a range of molecular weights (5-300 kDa) were still inactive (data not shown). Altogether, these results show that particle formation by Poly-7/8a is critical for mediating local DC activation and cytokine production. Increasing agonist density (3-10 mol% 7/8a) on PP-7/8a administered at the same dose of TLR-7/8a (62.5 nmol) led to higher expression of co-stimulatory molecules by macrophages/monocytes ( Fig. 3b ) and certain DC subsets ( Supplementary Fig. 6b ), as well as more persistent cytokine production ( Fig. 3c) . Furthermore, using PP-7/8a either at different doses of TLR-7/8a (1-62.5 nmol) or with a ~20-fold more potent agonist (PP-20x7/8a, Supplementary Fig. 2a,b ) led to higher-magnitude and more persistent (>8 d) cytokine responses ( Fig. 3d) . Consistent with recent in vitro findings that the C4 amine can be blocked to delay onset of immune activity 36 , we also found that reversing the orientation of TLR-7/8a on the polymers delayed the onset and reduced the magnitude of lymph node cytokine responses (Supplementary Fig. 7a-c) . Figure 2 Particle formation by Poly-7/8a enhances local retention and promotes uptake by migratory APCs. Dye-labeled particle-forming Poly-7/8a (PP-7/8a), polymer coil Poly-7/8a (PC-7/8a) and small molecule TLR-7/8a (SM 7/8a) were normalized for TLR-7/8a dose (62.5 nmol) and administered subcutaneously to the left hind footpad of mice (see Supplementary  Fig. 5a for material composition and doses). Based on the striking increase in innate immune activation by PP-7/8, CD8 + T cell and antibody responses were assessed following co-administration of the different adjuvant formulations with a model protein antigen, ovalbumin (OVA). After two immunizations, the magnitude of CD8 + T cell responses ( Fig. 3e,f) was concordant with that of local lymph node cytokine responses ( Fig. 3c,d) . PP-7/8a with high TLR-7/8a density (10 mol% TLR-7/8a) elicited substantially higher CD8 + T cell responses than were seen in all other groups (Fig. 3e) . Moreover, increasing either the dose of TLR-7/8a delivered with PP-7/8a or the potency of the agonists attached to PP-7/8a resulted in significantly increased magnitude of CD8 + T cell responses (Fig. 3f) . In assessing humoral immunity, although the magnitude of anti-OVA total IgG antibody responses was comparable between the different Poly-7/8a formulations ( Fig. 3g) , increasing density, potency and dose of TLR-7/8a delivered on polymer particles was associated with strikingly more biased antibody class switching to IgG2c (Fig. 3h,i and Supplementary  Fig. 8a-d) , consistent with the persistence of local IL-12 and IFN production driving the skewing of antibody responses to isotypes associated with T H 1 immunity.
Particulate formulation of other TLRa limits systemic toxicity
The local and systemic innate immune responses induced by PP-7/8a were then benchmarked against two commercially available TLRa, a small molecule TLR-7/8a, R848 (Resiquimod), and a TLR-9 agonist, CpG (ODN 1826). Whereas the low-molecularweight agonist, R848, induced only systemic (serum) cytokines ( Fig. 4a and Supplementary Fig. 9a) , the PP-7/8a induced predominantly local (lymph node) cytokine production ( Fig. 4b  and Supplementary Fig. 9b) . In contrast, CpG induced high levels of both local and systemic cytokine production (Fig. 4a,b and Supplementary Fig. 9a,b) . The systemic cytokine production (e-i) Poly-7/8a, SM 7/8a and controls were formulated with 50 µg of OVA in PBS and given subcutaneously to C57BL/6 mice at days 0 and 14 (see Supplementary Fig. 8a for doses). At day 28, tetramer + CD8 + T cell responses were evaluated from whole blood of mice that received either different formulations of TLR-7/8a (n = 5 per group) (e) or different doses or potencies of particle-forming Poly-7/8a (PP-7/8a) admixed with OVA (n = 5 per group) (f). Serum from vaccinated mice was evaluated for anti-OVA total IgG antibody titers (n = 5 per group) (g) as well as for the ratio of Ig1/IgG2c isotypes (n = 5 per group) (h,i). All data are representative of two or more independent experiments. Data on log scale are reported as geometric mean with 95% CI. Comparison of multiple groups for statistical significance was determined using Kruskal-Wallis ANOVA with Dunn's post hoc test; ns, not significant (P > 0.05); *P < 0.05; **P < 0.01.
npg
A r t i c l e s induced by R848 and CpG was associated with transient decreases in body weight (Fig. 4c) , which were not observed for locally retained PP-7/8a ( Fig. 4c,d) .
To extend these findings to other TLRa, particulate carriers of TLR-2/6a, TLR-4a and TLR-9a ( Supplementary Fig. 10 and Supplementary Methods) were compared with their respective (i) Splenocytes were isolated on day 70 and stimulated in vitro with an MML peptide pool. CD4 + T cells in the mixed splenocyte cultures were evaluated for T H 1-characteristic cytokine (IFNγ, IL-2 and TNFα) production (n = 4 per group). (j) Mice were challenged intradermally in both ears with L. major at day 70. Ear lesion diameters (n = 6 per group) were measured for 12 weeks (significance is shown for comparison with protein alone). All data are representative of two or more independent experiments, except that the L. major ear lesion kinetic is from a single study. Data on log scale are reported as geometric mean with 95% CI. Unless stated otherwise, comparison of multiple groups for statistical significance was determined using Kruskal-Wallis ANOVA with Dunn's post hoc test; ns, not significant (P > 0.05); *P < 0.05; **P < 0.01. Fig. 11a-d) . Delivery of the various TLRa on particulate carriers largely resulted in enhanced DC activation and lymph node cytokine production while reducing systemic cytokine production and morbidity relative to the unconjugated TLRa. Grouping data from several studies in a meta-analysis showed that the systemic cytokine production induced by unconjugated TLRa is associated with acute TLRa toxicity and morbidity (Supplementary Fig. 11e ).
unconjugated TLRa for local and systemic innate immune activation and morbidity (Supplementary

Particulate TLRa enhances protective T cell immunity
The adjuvant capacity of PP-7/8a, R848 and CpG to elicit protective CD8 + T cell responses was determined using OVA and SIV Gag protein as immunogens and Listeria monocytogenes (LM) expressing either OVA (LM-OVA) or SIV Gag (LM-Gag) for challenge to assess vaccine efficacy (Fig. 4e-h and Supplementary Fig. 12a-c) . After two immunizations with OVA protein, PP-7/8a and CpG (Fig. 4b) were associated with increased OVA-specific CD8 + T cell responses (12% and 8%, respectively) ( Fig. 4e ) and significant protection (5-and 4-log reductions in bacterial burden, respectively) against LM challenge ( Fig. 4g) . Of note, the magnitude of CD8 + T cell responses observed with PP-7/8a coadministered with OVA was ~10-fold higher than with SIV Gag (Fig. 5f) , and this was associated with far less protection against LM-Gag challenge (Fig. 4h) . Last, these studies were extended to show that PP-7/8a conferred T H 1 CD4 + T cell mediated protection in the mouse model of Leishmania major when used as an adjuvant (Fig. 4i,j and Supplementary Fig. 13 ).
In vivo particle formation with temperature-responsive Poly-7/8a
To substantiate the observation that particle scaffolds are critical for optimizing TLR-7/8a activity as an adjuvant and provide a potentially more flexible commercial platform for manufacturing and storage, we developed temperature-responsive polymer particle (TRPP)-7/8a conjugates (Supplementary Fig. 14a ) that exist as water-soluble macromolecules during manufacturing and storage (T < 30 °C) but undergo temperature-driven (T > 36 °C) particle assembly in vivo (Fig. 5a) . Although temperature-responsive polymers have been used as adjuvants alone 37 or to physically entrap admixed (that is, nonlinked) immunomodulators 38, 39 , herein we evaluated how varying densities of TLR-7/8a that are covalently linked directly to the polymer backbone influenced immune activity in vivo.
The transition temperature of TRPP-7/8a is tunable through modulation of the density and the hydrophilic or hydrophobic character of ligands attached to the polymer backbones ( Supplementary Fig. 14b) , allowing for production of TRPP-7/8a that form particles at precisely defined temperatures either in vitro or at body temperature in vivo (Fig. 5b,c) . Consistent with our earlier findings with PP-7/8a, only TRPP-7/8a capable of forming particles in vivo led to persistent and high-magnitude local cytokine production that was associated with protective CD8 + T cell responses and T H 1-skewed antibodies (Fig. 5d-f and Supplementary Fig. 14c-g) .
Steps were taken to further refine the structure of TRPP-7/8a to promote biodegradability and improve generalizability of the approach. First, di-block copolymers were used with ester side chains to promote degradation of the particles to individual polymer chains. Second, as prior studies by others and us have shown that synchronous delivery of protein antigen with innate immune stimulation is a highly efficient approach for optimizing T cell priming 10, 40, 41 , we prepared a TRPP-7/8a with coil peptides to provide a generalizable strategy for site-specifically linking antigen-coil fusion proteins to polymer carriers through coiled-coil interactions as described in previous reports 42, 43 . To demonstrate the utility of this approach for ensuring A r t i c l e s co-delivery of antigen and adjuvant, we prepared a recombinant HIV Gag-coil fusion protein site-specifically linked to a TRPP-7/8a through self-assembly using peptide-based coiled-coil interactions ( Fig. 6a and Supplementary Fig. 15a-d) . Mixing aqueous solutions of the HIV Gag-coil protein with a TRPP-7/8a modified with a complementary coil peptide resulted in self-assembly of a TRPP-7/8a-(coil-coil)-Gag heterodimer that undergoes particle formation (Fig. 6b,c) at temperatures greater than 34 °C and ensured co-delivery of Gag with TRPP-7/8a (Fig. 6d,e ). Co-delivery of Gag with TRPP-7/8a (TRPP-7/8a-(coil-coil)-Gag) resulted in enhanced T cell and antibody responses as compared with Gag-coil admixed with either the free TLR-7/8a or TRPP-7/8a ( Fig. 6f-i) .
DISCUSSION
Herein, we systematically refined properties of polymer-TLR-7/8a to elicit robust T cell and antibody responses to protein antigen. These studies established that particulate carriers (PP-7/8a) displaying high densities and potencies of TLR-7/8a are critical properties for promoting high-magnitude and persistent (>8 d) innate immune activation restricted to draining lymph nodes that is necessary for eliciting protective T H 1 CD4 + and CD8 + T cell responses and high antibody titers, while mitigating systemic innate immune activation that is associated with adjuvant toxicity and morbidity.
The data presented here extend earlier findings on particulate delivery of TLRa 15, 16 to additional TLRa (TLR-2/6a, TLR-4a, TLR-7/8a and TLR-9a) and show that, in the context of TLR-7/8a delivery, improved retention is necessary but not sufficient for enhancing T cell immunity. We find that despite improved retention at the injection site and draining lymph nodes by all polymer carriers of TLR-7/8a, only the particles (PP-7/8a) are taken up efficiently by APCs and induce persistent innate immune activation in draining lymph nodes. These findings provide additional mechanistic insights from studies by others and us that TLR-7/8a attached to protein antigens are markedly more immunogenic upon aggregation 44 or when adsorbed to alum microparticles 45 .
The patterns of DC uptake observed for the particulate Poly-7/8a (~700 nm) used in this study are consistent with earlier findings that ~100-to 1,000-nm particles are primarily trafficked to lymph nodes npg through uptake by migratory and monocyte-derived DCs 21, 22 ; however, it will be important to determine whether particulate carriers of TLR-7/8a that passively traffic to lymph nodes, or larger particles that require uptake by DCs in the periphery, are preferred for generating T cell immunity. Notably, most existing vaccines use alum microparticles that form depots to promote DC activation and antigen uptake in the periphery 8 . Moreover, direct intranodal injection of microparticle carriers of TLR-3a have been shown to be more immunogenic than intranodal injection of nanoparticles 14 . Thus, additional studies are needed to carefully characterize which sizes of particulate TLRa carriers are optimal for enhancing vaccine immunogenicity. Although this study used linear polymers based on HPMA and NIPAM as scaffolds for TLR-7/8a delivery, other particle-based delivery platforms have been used in formulations with TLRa (for example, poly(lactic-co-glycolic acid) (PLGA) [13] [14] [15] , liposomes 9, 17 and polymersomes 46 ) and can likely be adapted to satisfy the key physicochemical requirements for TLR-7/8a adjuvant activity defined herein. However, particulate delivery systems used in vaccines can be unstable during long-term storage and often require specialized manufacturing and storage conditions that contribute significantly to cost 8 . The temperature-responsive Poly-7/8a (TRPP-7/8a) reported herein could potentially overcome the manufacturing and storage limitations of pre-formed particles and may allow for the use of single-vial water-soluble preparations of both antigen and adjuvant.
Finally, it should be noted that other delivery approaches, such as albumin hitchhiking 18 or linear polymers that do not form particles but can promote local retention and efficient uptake by APCs in draining lymph nodes, may also provide the persistence of lymph node restricted innate immune activity that is needed to drive antibody and T cell responses. Indeed, as shown here, phosphorothioate-modified CpG oligodeoxynucleotides can induce protective T cell responses to protein antigen despite being relatively low-molecular-weight oligomers. This may be accounted for by local retention of CpG 47 through extracellular matrix protein binding 48 , durability through endonuclease resistance and uptake by APCs through lectin receptors 49 . Even so, numerous studies do demonstrate that the activity of CpG can be improved through formulation and delivery approaches 18, 50 .
In conclusion, polymer carriers of TLRa represent a diverse and versatile class of adjuvant that can be systematically tuned to achieve the optimal magnitude, quality and spatiotemporal characteristics of innate immune activity required for eliciting antibody and T cell immunity for applications in preventive and therapeutic vaccines for infections and tumors.
METHODS
Methods and any associated references are available in the online version of the paper. Millipore (Billerica, MA) and were run on a FLEX MAP3D multiplex system from Luminex (Austin, TX) according to the manufacturer's guidelines. Concentrations of individual cytokines in the supernatants were determined from standard curves.
Whole animal imaging. Biodistribution and kinetics of IR Dye-labeled materials was evaluated using a Bruker In Vivo Xtreme (Bruker, Billerica, MA) combined optical and X-ray small animal imaging system. Following subcutaneous administration of IR dye-labeled materials, mice were imaged at serial time points using a two-step imaging protocol: (1) epifluorescence (excitation = 760 nm; emission = 830 nm; 0.915 s exposure); followed by (2) X-ray (45 kVp; 1.0 s exposure). Amount of TLR-7/8a (nmol) within a region of interest (ROI) was calculated using a standard curve of (log(photons/mm 2 × seconds) versus TLR-7/8a amount (nmol).
Confocal microscopy of lymph node sections. 20 µm lymph node sections were prepared and imaged as previously described, with minor modifications 55 . In brief, lymph nodes were fixed with 0.05 M phosphate buffer containing 0.1 M L-lysine (pH 7.4), 2 mg/mL NaIO 4 , and 10 mg/mL paraformaldehyde over night at 4 °C, equilibrated in 30% sucrose solution for 24 h, fixed and sectioned using a Leica cryostat. Tissue sections were then blocked for 1-2 h with 1% normal mouse serum and bovine serum albumin solution containing 0.3% Triton X-100 and stained with directly conjugated antibodies for 6-10 h at 4 °C. Sections were then imaged using a Leica SP8 confocal microscope equipped with a 1.3NA 40× objective and a motorized tiling stage. Potential fluorescence spillover was removed using Channel Dye Separation analysis module in the Leica LAS AF software. Final image analysis was conducted using Imaris software (Bitplane, South Windsor, CT). For quantification, 3D isosurfaces of whole imaged lymph node sections were first generated using the Imaris surface creation module and statistics for the total surface volume and sum of AF488 fluorescence signal were exported into Excel (Microsoft, Redmond, WA) for further calculations.
Flow cytometry analysis of innate immune cells from lymph nodes and spleen.
The magnitude, activation status and adjuvant uptake of innate immune cells in draining lymph nodes and spleen were evaluated as previously described 44 , with slight modifications. Briefly, lymph nodes were harvested and added to pestle tubes for mechanical disruption as described above. Resulting lymph node cell suspensions were spun down, supernatant was removed and cells were re-suspended in 1 mL of an enzyme cocktail comprised of 1 mg/mL collagenase D (Roche, Basel, Switzerland) and 100 U/mL recombinant DNase I (Roche) in RPMI for 30 min at 37 °C. Lymph node cells were then washed and resuspended in PBS and added to 96 well plates for staining. To isolate splenocytes, 5 mL of enzyme cocktail was injected directly into spleens that were then incubated at 37 °C for 30 min. Spleens were mechanically disrupted over 70 µm nylon strainers (Corning) and collected in 50 mL Falcon tubes (Corning). Splenocytes were washed with HBSS and resuspended in 2 mL of ACK lysing buffer (Life Technologies) followed by incubation for 4 min at room temperature. Splenocytes were then washed with HBSS and then resuspended with PBS and added to 96 well plates for staining. Cells were stained with LIVE/DEAD cell stain (Aqua, Life Technologies) for 10 min at room temperature. Without washing, cells were stained for 15 min with FcR-Block, anti-CD16/CD32 (clone 2.4G2, BD Biosciences, Franklin Lakes, NJ), followed by the addition of Brilliant Violet (BV) 510-anti-CD3e (145-2C11, BD), BV421-anti-CD19 (1D3, BD), BV605-anti-Ly-6G (1A8, BD), BV786-anti-CD8 (53-6.7, BD), BV510-anti-NK-1.1 (PK136, BD), Cy7-PE-anti-B220 (RA3-6B2, BD), PE-anti-CD11c (HL3, BD), Ax700-anti-CD11b (M1/70, BioLegend, San Diego, CA), Cy5-PE-anti-F4/80 (BM8, eBioscience, San Diego, CA), and CF594-PE-anti-CD80 (16-10A1, BD). Following incubation in the antibody cocktail for 20 min, cells were washed with PBS, resuspended in 0.5% paraformaldehyde/PBS and then evaluated by flow cytometry.
Tetramer staining of CD8 + T cells from whole blood. Tetramer + CD8 + T cell responses were characterized from whole blood as previously described 56 . Briefly, 200 µL whole blood was collected from immunized mice in heparinized 1.5 mL polypropylene tubes at various time points described in the figure legends. Following red blood cell lysis using ACK Lysing buffer (Life Technologies), cells were washed with PBS and then added to 96 well plates for staining. Cells were stained with the viability dye LIVE/DEAD Fixable Orange (OrViD, Life Technologies) for 10 min at room temperature. After washing, cells were stained for 15 min with either PE-H-2Kb OVA (SIINFEKL) tetramer (Beckman Coulter, Brea, CA) or PE −H-2Db SIV Gag (AAVKNWMTQTL) tetramer (Beckman Coulter). Cells were then blocked with anti-CD16/CD32 (clone 2.4G2, BD) for 10 min, followed by the addition of APC-Cy7-anti-CD8 (53-6.7, BioLegend), PE-Cy7-anti-CD62L (MEL-14, Abcam, Cambridge, England), eFluor-660-anti-CD127 (A7R34, eBioscience) and FITC-anti-KLRG1 (2F1, Southern Biotech, Birmingham, AL). After incubating for 20 min at room temperature, cells were washed and then incubated with Fix/Perm solution (BD) for 20 min at 4 °C. After washing, cells were suspended in Perm/Wash buffer containing PerCP-Cy5.5-anti-CD3 (145-2C11, BD) and incubated at 4 °C for 30 min. Cells were washed and suspended in Perm/Wash buffer and then evaluated by flow cytometry.
Analysis of polyfunctional CD4 + T cell responses by flow cytometry.
Evaluation of polyfunctional CD4 + T cell responses was determined as previously described 57, 58 . Briefly, splenocytes were isolated from vaccinated mice at several time points and 1.5 × 10 6 splenocytes were cultured in 96 well plates with 2 µg/mL anti-CD28 (37.51, eBioscience) alone (background response), or in combination with 20 µg/mL MML protein (Leish-111f, derived from Leishmania spp.) or a 2 µg/mL solution of MML peptides (Mimotopes Pty Ltd; 15-mers overlapping by 11). Cells were incubated for 2 h before brefeldin A (BFA, Sigma-Aldrich) was added to a final concentration of 10 µg/ml and cells were incubated for an additional 4 h. After washing with PBS, cells were stained with Violet Dead Cell Stain (ViViD, Life Technologies), then washed and blocked with anti-CD16/CD32 (clone 2.4G2, BD) for 10 min at room temperature. After blocking, the following surface antibodies were added for 30 min at room temperature: APC-Cy7-anti-CD8 (clone 53-6.7, BioLegend) and Ax700-anti-CD4 (RM4-5). Cells were then fixed and permeabilized using Fix / Perm solution (BD) and incubated at 4 °C for 30 min. Cells were washed and then suspended in Perm/Wash buffer containing PE-Cy5-anti-CD3 (145-2C11, BD), APC-anti-IFNγ (XMG1.2, BD), PE-anti-IL-2 (JES6-5H4, BD), PE-Cy7-anti-TNFα (MP6-XT22, BD) for 30 min at room temperature. Cells were washed and suspended in Perm/Wash buffer and then evaluated by flow cytometry. 
